

Phone: +49-40-8532600 or 0800-2466651 (D) +49-40-85326022 or 0800-2466652 (D)



## **Mouse Monoclonal Antibody to**

# EGFR (phospho-Tyr 1045)

## clone 11C2

0136-100/EGFR-11C2 Order No.:

100 Size (µg) 0136S Lot No.:

Mol. Weight **Ref.Cell Line** Isotype **Species Reactivity Applications Epitope Immunogen** 

IgG1 human, mouse ELISA, WB, IP, 180 kDa HepG2 Phosphotyrosine pY1045 Phosphopeptide LQR pYSSD Luminex conjugated to KLH

#### **Background and Specificity:**

EGFR/erbB receptors are activated upon binding of EGF and EGF-related growth factors such as TGF alpha, beta-cellulin, Hb-EGF, HRG, or NRG. Binding of these ligands leads to receptor homo- and heterodimerization followed by autophosphorylation and activation of downstream signal transduction pathways (MAPK, PI3K/PKB, and STAT). In addition, EGFR becomes fully activated after phosphorylation of Y845 by src family kinases.

Phosphorylation of Y1045 leads to association with cbl and subsequent receptor degradation. Phosphorylation of S1047 by CamKinase II leads to attenuation of kinase activity; phosphorylation of T654 (by PKC) and T669 (by MAPK, p38) interferes with receptor endocytosis/recycling.

Mab EGFR-11C2 specifically recognizes EGFR phosphorylated at Tyrosine 1045. It is suitable for Western Blot and ELISA applications.

The antibody was purified from serum-free cell culture **Purification:** 

supernatant by subsequent thiophilic adsorption and size

exclusion chromatography.

Formulation: liquid; 0.1mg/ml in in PBS/0.09% Na-Azide/PEG and

Sucrose/50% Glycerol

Reconstitution:

Aliquote and store at -20°C up to 1 year. Stability:

Avoid repeated freeze / thaw cycles.

#0812: Cell lysate from pervanadate-treated HepG2 cells **Positive Control:** 

Immunoblotting: 0.5 µg/ml for HRPO/ECL detection

> Recommended blocking buffer: Casein/Tween 20 based blocking and blot incubation buffer, e.g. nanoTools product

#3031-500/CPPT or #3031-3000/CPPT.

Immunoprecipitation: use at 1 - 10 µg per 10<sup>6</sup> pervanadate-treated A431 cells

ND Immunocytochemistry:

use at 0.05 µg/ml ELISA:

> All products are supplied for research and investigational use only. Not for use in humans or laboratory animals.

### **Related Products**

01/260207F

Blocking peptide for mab EGFR-11C2

#2004-100/EGFR pTyr1045

mab to EGFR (C-terminus) #0007-100/EGFR-13G8

mab to EGFR (cytoplasmic domain)

#0168-100/EGFR-10F mab to EGFR (extracellular domain)

#0209-100/EGFR-20E1:

mab to EGFR (aa 960 - 980)

mab to EGFR (N-terminus)

#0201-100/EGFR-1 mab to phospho-EGFR (pY 845)

#0116-100/EGFR-12A3

mab to phospho-EGFR (pY1068)

#0187-100/FGFR-15A

mab to phospho-EGFR (pY 1086)

mab to phospho-EGFR (pY 1148)

#0219-100/EGFR-10G

mab to phospho-EGFR (pY1173)

#0008-100/EGFR-9H2

mab to dephospho-EGFR (Y1173)

#0009-100/EGFR-20G3 mab to phospho-EGFR (pT669)

#0191-100/EGFR-5F10


mab to phospho-EGFR (pT654)

#0138-100/FGFR-3F2

mab to phospho-EGFR (pS1047)

#0107-100/EGFR-1H9

For monoclonal antibodies against erbB2, phospho-erbB2, erbB3 and erbB4, as well as against various EGFR downstream targets, please refer to our website at www.nanotools.de



#### **EGFR** activation

Serum starved MDA-MB 468 cells were incubated with 10 ng/ml EGF for the indicated times. Whole cell lysates were prepared with lysis buffer V19 and separated by SDS-PAGE (ca 20.000 cells/lane). The immunoblot was probed with mab EGFR-11C2 (0.5 µg/ ml) for 1h at RT and developed by ECL (exp. time: 30 sec).

lane 1: control; lane 2: 5 min EGF; lane 3: 15 min EGF; lane 4: 30 min EGF; lane 5: 1h EGF; lane 6; 2h EGF; lane 7: 4h EGF; lane 8: 8h EGF